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Effect of Cediranib, Temozolamide and 
Radiotherapy in U87 GBM wtEGFR and 
EGFRvIII-expressing Xenografts
Introduction
Glioblastomas (GBM) frequently overexpress the epidermal growth 
factor receptor (wtEGFR) or its mutant, EGFRvIII contributing to 
radioresistance. New treatment strategies for GBM include blockade 
of EGFR signaling and angiogenesis. Cediranib (CD) is a highly potent 
VEGFR-2 RTKI that inhibits all three VEGF receptors. This study 
investigated the radiosensitizing potential of CD in combination with 
temozolamide (TMZ) in U87 GBM xenografts expressing wtEGFR 
or EGFRvIII.
Method
U87 GBM cells transfected with wtEGFR or EGFRvIII were injected 
into the hind limbs of nude mice. CD was dosed at 3 mg/kg daily 
(days 0-9); TMZ at 10 mg/kg on day 0. Radiotherapy (RT) consisted 
of 3 fractions of 5 Gy (days 0-2). VEGF was assayed from culture 
media 48 hr after treatment.
Results
In U87 EGFRvIII xenografts, RT, CD or TMZ alone significantly 
increased tumor doubling time (T2x), when compared to control 
(4.6, 4.85 and 4.31 for CD, RT and TMZ respectively vs. 3.0 for 
control). TMZ + RT, but not CD+ RT, was significantly better than 
RT alone (T2x = 6.22 vs. 4.85 respectively). However, CD + TMZ was 
significantly better than TMZ alone (T2x = 6.3 for cediranib + TMZ 
vs. 4.3 for TMZ). The triple combination of CD, TMZ and RT was 
significantly better than RT alone. In U87 wtEGFR xenografts, single 
agent RT and TMZ were significantly better than control (T2x =7.84 
and 6.72 for RT and TMZ respectively vs. 3.45 for control). Single 
agent CD marginally increased T2x compared to control (4.69 vs. 3.45, 
NS). CD + TMZ was significantly better than TMZ alone (T2x = 11.63 
vs. 6.72 respectively). The triple combination of CD, TMZ and RT 
was marginally better than RT alone but did not reach significance. 
In cell culture, TMZ, stimulated VEGF secretion from both U87 
wtEGFR and U87 EGFRvIII cells; however, VEGF levels were higher 
from U87 EGFR cells than U87 EGFRvIII cells.
Conclusion
CD appears to be effective in GBM, both as a single agent and when 
combined with TMZ. Tumors expressing EGFRvIII were more 
sensitive than tumors expressing wtEGFR, possibly due to inability 
of CD to overcome excessive VEGF secretion by the latter.
Support: AstraZeneca Pharmaceuticals and the Radiation Therapy 
Oncology Group.
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